Novo Nordisk shares tumble as weight-loss drug trial data disappoints
Obesity drug CagriSema misses goal of 25% body weight reduction
Full Article
Novo Nordisk shares tumble as weight-loss drug trial data disappoints
FT.com
0 shares
1 views